TD Asset Management’s Kyverna Therapeutics KYTX Stock Holding History

TD Asset Management’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.46M	Sell	169,082 -53,714	-24%	-$448K	﹤0.01%	1033
2025 Q4	$2.09M	Buy	222,796 +58,000	+35%	+$431K	﹤0.01%	971
2025 Q3	$989K	Sell	164,796 -87,400	-35%	-$349K	﹤0.01%	1094
2025 Q2	$774K	Buy	252,196 +161,954	+179%	+$401K	﹤0.01%	1093
2025 Q1	$174K	Hold	90,242	–	–	﹤0.01%	1199
2024 Q4	$338K	Hold	90,242	–	–	﹤0.01%	1204
2024 Q3	$472K	Hold	90,242	–	–	﹤0.01%	1304
2024 Q2	$677K	Buy	+90,242	New	+$1.38M	﹤0.01%	1227

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

TD Asset Management's KYTX Position: Q1 2026 in Review

TD Asset Management reduced its Kyverna Therapeutics (KYTX) stake by 24% in Q1 2026, selling an estimated $448K and leaving 169,082 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1033.

TD Asset Management first reported a position in KYTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.09M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

TD Asset Management held 169,082 shares of Kyverna Therapeutics worth $1.46M as of Q1 2026.
TD Asset Management sold 53,714 Kyverna Therapeutics shares in Q1 2026, an estimated $448K.
Kyverna Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1033 holding.
TD Asset Management first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 8 quarters since.
TD Asset Management's Kyverna Therapeutics position peaked at $2.09M in Q4 2025.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.